4-Aza-17ଲ-substituted-5-androstan-3-one-reductase inhibitors
Patent 4377584 Issued on March 22, 1983. Estimated Expiration Date: 
September 23, 2000. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 23, 2000. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2227876 3239417 3264301 3285918 Inventors
AssigneeApplicationNo. 06/189981 filed on 09/23/1980US Classes:514/284, Tetracyclo ring system having the six-membered hetero ring as one of the cyclos514/212.04, Polycyclo ring system having the seven-membered hetero ring as one of the cyclos514/859, Acne514/864, Seborrhea540/576, Polycyclo ring system which contains the hetero ring as one of the cyclos546/15, Spiro546/152, Quinolines (including hydrogenated)546/77, The six-membered hetero ring shares ring members with one other cyclo only546/78Plural chalcogens bonded directly to carbocyclic rings of the tetracyclo ring system (e.g., pyridoanthraquinones, etc.)ExaminersPrimary: Coughlan, Paul M. Jr.Attorney, Agent or FirmInternational ClassesC07J 41/00 (20060101)C07J 73/00 (20060101) C07J 17/00 (20060101) C07J 33/00 (20060101) C07J 11/00 (20060101) C07J 43/00 (20060101) C07J 3/00 (20060101) Abstract4-Aza-17ଲ-substituted-5-androstan-3-ones and their A-homo analogs of the formula: ##STR1## where Formula (I) may also have the structure of partial Formulas (II) and/or (III);and pharmaceutically acceptable salts of the above compounds are active as testosterone 5-reductase inhibitors, and thus useful topically for treatment of acne, seborrhea, female hirsutism, and systemically in treatment of benign prostatic hypertrophy.Other References
|
| ||||||||||||||
